Citations

Showing 10 of 108119 citations.

Tuberculosis in Children
Holmberg, Peter J., Temesgen, Zelalem , Banerjee, Ritu

Mayo Clinic

Pediatrics In Review | April 1, 2019 | Volume: 40 | Issue: 4 | Pages: 168-178

10.1542/pir.2018-0093 | PMID 30936398 Get It

Epidemiology of Children With Multiple Complex Chronic Conditions in a Mixed Urban-Rural US Community
Bjur, Kara A. , Ryu, Euijung , Crow, Sheri, Juhn, Young J. , Crow, Sheri S, King, Katherine S. , Wi, Chung‐Il

Mayo Clinic

Hospital Pediatrics | April 1, 2019 | Volume: 9 | Issue: 4 | Pages: 281-290

10.1542/hpeds.2018-0091 | PMID 30923070 Get It

OBJECTIVES:Children with multiple complex chronic conditions (MCCs) represent a small fraction of our communities but a disproportionate amount of health care cost and mortality. Because the temporal trends of children with MCCs within a geographically well-defined US pediatric population has not been previously assessed, health care planning and policy for this vulnerable population is limited.METHODS:In this population-based, repeated cross-sectional study, we identified and enrolled all eligible children residing in Olmsted County, Minnesota, through the Rochester Epidemiology Project, a medical record linkage system of Olmsted County residents. The pediatric complex chronic conditions classification system version 2 was used to identify children with MCCs. Five-year period prevalence and incidence rates were calculated during the study period (1999–2014) and characterized by age, sex, ethnicity, and socioeconomic status (SES) by using the housing-based index of socioeconomic status, a validated individual housing-based SES index. Age-, sex-, and ethnicity-adjusted prevalence and incidence rates were calculated, adjusting to the 2010 US total pediatric population.RESULTS:Five-year prevalence and incidence rates of children with MCCs in Olmsted County increased from 1200 to 1938 per 100 000 persons and from 256 to 335 per 100 000 person-years, respectively, during the study period. MCCs tend to be slightly more prevalent among children with a lower SES and with a racial minority background.CONCLUSIONS:Both 5-year prevalence and incidence rates of children with MCCs have significantly increased over time, and health disparities are present among these children. The clinical and financial outcomes of children with MCCs need to be assessed for formulating suitable health care planning given limited resources.
Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms?
Huston, Jessica , Frantz, Robert P. , Frantz, Robert P , Brittain, Evan L

Mayo Clinic

Pulmonary Circulation | April 1, 2019 | Volume: 9 | Issue: 2 | Pages: 1-8

10.1177/2045894019844994 | PMID 30931829 Get It

Pulmonary arterial hypertension (PAH) is a rare disease that carries a poor prognosis. For 45 years, the definition of pulmonary hypertension (PH) has been a mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg, based on expert opinion. Recent data indicate that the mortality risk starts in the mPAP range of 21–24 mmHg, which has recently been reflected in the World Symposium on PH consensus document defining PH as a mPAP > 20 mmHg. The mortality associated with these lower levels of pulmonary pressures suggests that these values reflect a more advanced disease stage than previously recognized. It is unknown whether interventions targeting patients with mPAP values in the range of 21–24 mmHg in the absence of left ventricular or hypoxic lung disease are of clinical benefit. Here we present historical perspective on the hemodynamic definition of PH, discuss recent epidemiologic data, and outline obstacles to enrolling and evaluating response to therapy in mild PAH patients, as well as potentially useful study designs.
Epidemiology of Hand and Wrist Injuries in NCAA Men’s Football: 2009–2010 to 2013–2014
Bartels, Douglas W., Hevesi, Mario, Macalena, Jeffrey A. , Krych, Aaron J. , Wyles, Cody, Krych, Aaron J , Macalena, Jeffrey A , Bartels, D , Hevesi, Mario , Wyles, Cody C. , Kakar, Sanjeev

Mayo Clinic

Orthopaedic Journal of Sports Medicine | April 1, 2019 | Volume: 7 | Issue: 4 | Pages: No page available

10.1177/2325967119835375 | PMID 30968051 Get It

Background: Participation in National Collegiate Athletic Association (NCAA) football is at an all-time high. This population of athletes experiences a substantial injury burden, with many injuries affecting the upper extremities. Purpose/Hypothesis: The purpose of this study was to describe the epidemiology of hand and wrist injuries in college football players from the academic years 2009–2010 to 2013–2014. We hypothesized that variables such as event type (practice vs game), mechanism of injury, and player position would have an effect on the injury incidence. Study Design: Descriptive epidemiological study. Methods: An epidemiological study utilizing the NCAA Injury Surveillance Program was performed to investigate rates and patterns of hand and wrist injuries in participating varsity football teams from 2009–2010 to 2013–2014. Results: A total of 725 hand and wrist injuries were captured in 899,225 athlete-exposures. The observed practice injury rate was 0.51 injuries per 1000 athlete-exposures, compared with a game injury rate of 3.60 ( P < .01). Player-on-player contact was the most common injury mechanism reported, with blocking being the most common activity at the time of injury. Offensive linemen were most likely to experience an injury. Of all injuries sustained, 71.4% resulted in no time loss from competition, whereas 9.8% of injuries resulted in longer than 7 days of time loss. A fracture resulted in the greatest time loss from competition (mean ± SD, 8.3 ± 24.0 days; median, 0 days [range, 0-148 days] for injuries sustained in a practice setting) (mean ± SD, 7.7 ± 15.8 days; median, 0 days [range, 0-87 days] for injuries sustained in a game setting). Conclusion: Hand and wrist injuries were found to be significantly more common in games when compared with practices. This study provides valuable prognostic data regarding expected time loss on a per-injury pattern basis. Further investigation on specific injury subtypes and expected time loss as a result of these injures would provide trainers, players, and coaches with useful information on an expected postinjury recovery and rehabilitation timeline.
Current and promising therapy for primary biliary cholangitis
Gossard, Andrea A., Lindor, Keith D.

Mayo Clinic

Expert Opinion on Pharmacotherapy | April 1, 2019 | Volume: 20 | Issue: 9 | Pages: 1161-1167

10.1080/14656566.2019.1601701 | PMID 30931642 Get It

Computed Tomography–Based Indexed Aortic Annulus Size to Predict Prosthesis-Patient Mismatch
Head, Stuart J., Reardon, Michael J. , Deeb, G. Michael, Popma, Jeffrey J. , Gleason, Thomas G. , Williams, Mathew , Radhakrishnan, Sam, Oh, Jae K. , Chang, Yanping, Boulware, Michael J., Investigators, for the SURTAVI, Reardon, Michael J , Deeb, G. Michael , Mieghem, Nicolas M. Van , Fremes, Stephen E. , Kappetein, A. Pieter , Investigators, for the SURTAVI, Williams, Mathew

Mayo Clinic

Circulation: Cardiovascular Interventions | April 1, 2019 | Volume: 12 | Issue: 4 | Pages: No page available

10.1161/circinterventions.118.007396 | PMID 30929507 Get It

Background: Hemodynamic performance of prostheses after transcatheter aortic valve replacement (TAVR) is generally better than after surgical aortic valve replacement (SAVR), especially in patients with a small native annulus size. However, it remains unclear whether differences are consistent for patients with a different propensity for developing prosthesis-patient mismatch (PPM), considering annulus size and body size of patients. Methods and Results: The SURTAVI trial (Surgical Replacement and Transcatheter Aortic Implantation) compared TAVR using a self-expandable valve with SAVR in intermediate-risk patients. Multidetector computed tomography–based aortic annulus size consisted of the perimeter-derived diameter, which was divided by body surface area to produce an indexed annulus size. Patients were categorized into a small (9–12 mm/m 2 ), medium (>12–14 mm/m 2 ), and large (>14–18 mm/m 2 ) group according to indexed annulus size. We compared TAVR and SAVR for PPM, hemodynamics, and clinical, and functional outcomes through 1-year follow-up within the size groups. Patients who underwent TAVR received a larger prosthesis with increasing indexed annulus size ( P <0.001), while there was no difference in prosthesis size in patients who underwent SAVR ( P =0.74). Patients in all size groups had significantly larger indexed effective orifice area and lower mean gradients at discharge after TAVR versus SAVR. Rates of PPM were significantly lower with TAVR versus SAVR in all groups ( P <0.001) and declined with larger indexed annulus sizes with both TAVR ( P =0.04) and SAVR ( P =0.03). Indexed annulus size was an independent predictor of PPM after TAVR and SAVR. Clinical outcomes were comparable between TAVR and SAVR across all groups, apart from a significantly higher rate of reintervention after TAVR versus SAVR in the large indexed annulus size group (2.5% versus 0%; P =0.01) but without significant interaction ( P int =0.81). Conclusions: Rates of PPM were significantly lower after TAVR than after SAVR across all groups of indexed annulus size, reflecting better hemodynamic performance of transcatheter versus surgical valves, irrespective of the propensity to develop PPM. More attention should be directed to prevention of PPM after SAVR. This information should be considered by the Heart Team to recommend a specific procedure or valve. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01586910.
CRRL269
Chen, Yang , Harty, Gail J., Zheng, Ye , Sugihara, Shinobu , Sangaralingham, S. Jeson , Ichiki, Tomoko , Grande, Joseph P. , Lee, Hon-Chi, Wang, Xiaoli , Burnett, John C. , Iyer, Seethalakshmi R., Iyer, Seethalakshmi , Sangaralingham, S. Jeson

Mayo Clinic

Circulation Research | April 1, 2019 | Volume: 124 | Issue: 10 | Pages: 1462-1472

10.1161/circresaha.118.314164 | PMID 30929579 Get It

Rationale: Acute kidney injury (AKI) has a high prevalence and mortality in critically ill patients. It is also a powerful risk factor for heart failure incidence driven by hemodynamic changes and neurohormonal activation. However, no drugs have been approved by the Food and Drug Administration. Endogenous pGC-A (particulate guanylyl cyclase A receptor) activators were reported to preserve renal function and improve mortality in AKI patients, although hypotension accompanied by pGC-A activators have limited their therapeutic potential. Objective: We investigated the therapeutic potential of a nonhypotensive pGC-A activator/designer natriuretic peptide, CRRL269, in a short-term, large animal model of ischemia-induced AKI and also investigated the potential of uCNP (urinary C-type natriuretic peptide) as a biomarker for AKI. Methods and Results: We first showed that CRRL269 stimulated cGMP generation, suppressed plasma angiotensin II, and reduced cardiac filling pressures without lowering blood pressure in the AKI canine model. We also demonstrated that CRRL269 preserved glomerular filtration rate, increased renal blood flow, and promoted diuresis and natriuresis. Further, CRRL269 reduced kidney injury and apoptosis as evidenced by ex vivo histology and tissue apoptosis analysis. We also showed, compared with native pGC-A activators, that CRRL269 is a more potent inhibitor of apoptosis in renal cells and induced less decreases in intracellular Ca 2+ concentration in vascular smooth muscle cells. The renal antiapoptotic effects were at least mediated by cGMP/PKG pathway. Further, CRRL269 inhibited proapoptotic genes expression using a polymerase chain reaction gene array. Additionally, we demonstrated that AKI increased uCNP levels. Conclusions: Our study supports developing CRRL269 as a novel renocardiac protective agent for AKI treatment.
Genetic features associated with 18F-FDG uptake in intrahepatic cholangiocarcinoma
Ahn, Keun Soo , Kang, Koo Jeong , Kim, Yong‐Hoon , Kim, Tae-Seok, Song, Bong‐Il , Kim, Hae Won , O’Brien, Daniel R. , Roberts, Lewis R. , Won, Kyoung Sook , Roberts, Lewis R , Kim, Tae‐Seok , Lee, Jeong Woo

Mayo Clinic

Annals of Surgical Treatment and Research | April 1, 2019 | Volume: 96 | Issue: 4 | Pages: 153

10.4174/astr.2019.96.4.153 | PMID 30941318 Get It

Early Magnetic Resonance Imaging–Based Changes in Patients With Meniscal Tear and Osteoarthritis: Eighteen‐Month Data From a Randomized Controlled Trial of Arthroscopic Partial Meniscectomy Versus Physical Therapy
Collins, Jamie E. , Marx, Robert G. , Jarraya, Mohamed , Levy, Bruce A. , Mandl, Lisa A. , Wright, Rick W. , Group, the MeTeOR Investigator, Brophy, Robert H. , Losina, Elena , Brophy, Robert H. , Collins, Jamie E , Losina, Elena , Marx, Robert G. , Guermazi, Ali , Jones, Morgan H. , Martin, Scott D. , Spindler, Kurt P , Katz, Jeffrey N. , Group, the MeTeOR Investigator

Mayo Clinic

Arthritis Care & Research | April 1, 2019 | Volume: 72 | Issue: 5 | Pages: 630-640

10.1002/acr.23891 | PMID 30932360 Get It

ObjectiveThe present study was undertaken to evaluate changes in knee magnetic resonance imaging (MRI) findings over the course of 18 months in subjects with osteoarthritic change and meniscal tear treated with arthroscopic partial meniscectomy (APM) or nonoperatively with physical therapy (PT).MethodsWe used 18‐month follow‐up data from the Meniscal Tear in Osteoarthritis Research Trial. MRI results were read with reference to the MRI Osteoarthritis Knee Score. We focused on 18‐month change in bone marrow lesions (BMLs), cartilage thickness, cartilage surface area, osteophyte size, effusion‐synovitis, and Hoffa‐synovitis. We used multinomial logistic regression to assess associations between MRI‐based changes in each feature and treatment type.ResultsA total of 351 subjects were randomized, and 225 had both baseline and 18‐month MRI results. In both treatment groups, patients experienced substantial changes in several MRI‐based markers. In 60% of the APM group, versus 33% of the PT group, cartilage surface area damage advanced in ≥2 subregions (adjusted odds ratio 4.2 [95% confidence interval 2.0–9.0). Patients who underwent APM also had greater advancement in scores for osteophytes and effusion‐synovitis. We did not find significant associations between treatment type and change in cartilage thickness, BMLs, or Hoffa‐synovitis.ConclusionThis cohort of patients with meniscal tear and osteoarthritis showed marked advancement in MRI‐based features over 18 months. Patients treated with APM showed more advancement in some features compared to those treated nonoperatively. The clinical relevance of these early findings is unknown and requires further study.